Stem definition | Drug id | CAS RN |
---|---|---|
angiotensin II receptor antagonists, antihypertensive (non-peptidic) | 4322 | 863031-21-4 |
Dose | Unit | Route |
---|---|---|
40 | mg | O |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 25, 2011 | FDA | ARBOR PHARMS IRELAND |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Renal impairment | 49.38 | 21.52 | 33 | 1850 | 74339 | 46609840 |
Hepatic function abnormal | 43.08 | 21.52 | 23 | 1860 | 34398 | 46649781 |
Cerebral infarction | 42.14 | 21.52 | 20 | 1863 | 23346 | 46660833 |
Platelet count decreased | 32.40 | 21.52 | 29 | 1854 | 99995 | 46584184 |
Hyperkalaemia | 30.05 | 21.52 | 21 | 1862 | 50688 | 46633491 |
Hypertension | 28.18 | 21.52 | 37 | 1846 | 196319 | 46487860 |
Decreased appetite | 25.48 | 21.52 | 35 | 1848 | 193801 | 46490378 |
Product odour abnormal | 23.30 | 21.52 | 6 | 1877 | 1130 | 46683049 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cerebral infarction | 90.35 | 20.94 | 43 | 2281 | 26330 | 29923824 |
Hepatic function abnormal | 69 | 20.94 | 42 | 2282 | 41903 | 29908251 |
Renal impairment | 60.77 | 20.94 | 51 | 2273 | 84133 | 29866021 |
Fibrillary glomerulonephritis | 53.23 | 20.94 | 8 | 2316 | 41 | 29950113 |
Interstitial lung disease | 46.57 | 20.94 | 38 | 2286 | 60159 | 29889995 |
Proteinuria | 31.29 | 20.94 | 18 | 2306 | 16127 | 29934027 |
Nephrotic syndrome | 29.06 | 20.94 | 13 | 2311 | 6872 | 29943282 |
Thrombotic cerebral infarction | 27.25 | 20.94 | 6 | 2318 | 299 | 29949855 |
Altered state of consciousness | 25.36 | 20.94 | 17 | 2307 | 19902 | 29930252 |
Hepatocellular carcinoma | 24.94 | 20.94 | 13 | 2311 | 9597 | 29940557 |
Hyperuricaemia | 22.09 | 20.94 | 11 | 2313 | 7383 | 29942771 |
Haemorrhagic cerebral infarction | 21.60 | 20.94 | 6 | 2318 | 780 | 29949374 |
Decreased appetite | 21.21 | 20.94 | 40 | 2284 | 149870 | 29800284 |
Source | Code | Description |
---|---|---|
ATC | C09CA09 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN Angiotensin II receptor blockers (ARBs), plain |
ATC | C09DA09 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs) and diuretics |
MeSH PA | D047228 | Angiotensin II Type 1 Receptor Blockers |
MeSH PA | D057911 | Angiotensin Receptor Antagonists |
FDA MoA | N0000180999 | Angiotensin 2 Type 1 Receptor Antagonists |
FDA EPC | N0000175561 | Angiotensin 2 Receptor Blocker |
FDA PE | N0000178477 | Decreased Blood Pressure |
CHEBI has role | CHEBI:35674 | antihypertensive |
CHEBI has role | CHEBI:50266 | prodrugs |
CHEBI has role | CHEBI:61016 | angiotensin receptor antagonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Hypovolemia | contraindication | 28560003 | |
Low blood pressure | contraindication | 45007003 | |
Hyponatremia | contraindication | 89627008 | |
Impaired renal function disorder | contraindication | 197663003 | |
Pregnancy, function | contraindication | 289908002 | |
Renal artery stenosis | contraindication | 302233006 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.11 | acidic |
pKa2 | 3.02 | Basic |
pKa3 | 2.4 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Type-1 angiotensin II receptor | GPCR | ANTAGONIST | UNKNOWN | CHEMBL | |||||
Type-1 angiotensin II receptor | GPCR | IC50 | 6.38 | CHEMBL |
ID | Source |
---|---|
WEC6I2K1FC | UNII |
D08067 | KEGG_DRUG |
863031-24-7 | SECONDARY_CAS_RN |
147403-03-0 | SECONDARY_CAS_RN |
4030593 | VANDF |
4030594 | VANDF |
C2698290 | UMLSCUI |
C1958569 | UMLSCUI |
CHEBI:68845 | CHEBI |
CHEBI:68850 | CHEBI |
CHEMBL2103795 | ChEMBL_ID |
CHEMBL2028661 | ChEMBL_ID |
DB08822 | DRUGBANK_ID |
CHEMBL57242 | ChEMBL_ID |
23699544 | PUBCHEM_CID |
8874 | INN_ID |
C557413 | MESH_SUPPLEMENTAL_RECORD_UI |
6900 | IUPHAR_LIGAND_ID |
C521273 | MESH_SUPPLEMENTAL_RECORD_UI |
8724 | INN_ID |
F9NUX55P23 | UNII |
135415867 | PUBCHEM_CID |
6901 | IUPHAR_LIGAND_ID |
1091642 | RXNORM |
180314 | MMSL |
27787 | MMSL |
d07754 | MMSL |
013661 | NDDF |
013662 | NDDF |
448917007 | SNOMEDCT_US |
449042005 | SNOMEDCT_US |
449561004 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Edarbi | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60631-040 | TABLET | 40 mg | ORAL | NDA | 32 sections |
Edarbi | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60631-080 | TABLET | 80 mg | ORAL | NDA | 32 sections |
Edarbyclor | HUMAN PRESCRIPTION DRUG LABEL | 2 | 60631-412 | TABLET | 40 mg | ORAL | NDA | 32 sections |
Edarbyclor | HUMAN PRESCRIPTION DRUG LABEL | 2 | 60631-425 | TABLET | 40 mg | ORAL | NDA | 32 sections |